Yaqi Zhao

ORCID: 0000-0002-8230-5312
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Lepidoptera: Biology and Taxonomy
  • RNA Interference and Gene Delivery
  • Genomics and Phylogenetic Studies
  • Immunotherapy and Immune Responses
  • Animal Genetics and Reproduction
  • RNA modifications and cancer
  • Lung Cancer Treatments and Mutations
  • Acute Myeloid Leukemia Research
  • Sperm and Testicular Function
  • Immune Cell Function and Interaction
  • Ferroptosis and cancer prognosis
  • Childhood Cancer Survivors' Quality of Life
  • Plant-Microbe Interactions and Immunity
  • Plant Disease Resistance and Genetics
  • Tuberculosis Research and Epidemiology
  • Advanced biosensing and bioanalysis techniques
  • Xenotransplantation and immune response
  • Biochemical Analysis and Sensing Techniques
  • Biosensors and Analytical Detection

Chinese Academy of Medical Sciences & Peking Union Medical College
2025

Huazhong University of Science and Technology
2025

Union Hospital
2025

St. Jude Children's Research Hospital
2018-2024

Tianjin Medical University
2023-2024

Memorial Sloan Kettering Cancer Center
2024

Mayo Clinic in Arizona
2024

Johns Hopkins University
2024

Dana-Farber Cancer Institute
2024

Medical College of Wisconsin
2024

Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, BCL-XL/BCL2 may allow targeting of both and BCL-XL without dose-limiting thrombocytopenia associated navitoclax monotherapy. The safety preliminary efficacy venetoclax chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) pediatric adult patients relapsed/refractory (R/R) acute lymphoblastic leukemia or lymphoma. Forty-seven received treatment. A recommended II dose 50 mg for adults 25 <45 kg...

10.1158/2159-8290.cd-20-1465 article EN Cancer Discovery 2021-02-16

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having measurable residual disease (MRD)-negative complete remission combination chemotherapy. The addition of blinatumomab, bispecific T-cell engager molecule that is approved for the treatment relapsed, refractory, and MRD-positive BCP-ALL, may efficacy in patients MRD-negative remission.

10.1056/nejmoa2312948 article EN New England Journal of Medicine 2024-07-24

Summary Southern leaf blight (SLB), caused by the necrotrophic fungal pathogen Cochliobolus heterostrophus (anamorph Bipolaris maydis ), is a major foliar disease which causes significant yield losses in maize worldwide. A quantitative trait locus, qSLB 3.04 , conferring recessive resistance to SLB was previously mapped on chromosome 3. Using combination of map‐based cloning, association analysis, ethyl methanesulfonate and transposon mutagenesis, CRISPR‐Cas9 editing, we demonstrate that...

10.1111/nph.18781 article EN cc-by-nc New Phytologist 2023-02-01

Abstract The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterations the efficacy InO. Of 326 randomized patients, 91 (InO, n = 43; SC, 48) had samples evaluable analysis. spectrum gene fusions other...

10.1182/bloodadvances.2023012430 article EN cc-by-nc-nd Blood Advances 2024-04-12

MADS-box genes encode transcription factors that are known to be involved in several aspects of plant growth and development, especially floral organ specification. To date, the comprehensive analysis potato gene family is still lacking after completion genome sequencing. A genome-wide characterization, classification, expression factor was performed this study. total 153 were identified categorized into MIKC subfamily (MIKCC MIKC*) M-type (Mα, Mβ, Mγ) based on their phylogenetic...

10.1186/s12864-018-5113-z article EN cc-by BMC Genomics 2018-10-03

Plant non-specific lipid transfer proteins (nsLTPs) are small, basic that abundant in higher plants. They have been reported to play an important role various plant physiological processes, such as transfer, signal transduction, and pathogen defense. To date, a comprehensive analysis of the potato nsLTP gene family is still lacking after completion (Solanum tuberosum L.) genome sequencing. A genome-wide characterization, classification expression StnsLTP was performed this study. In study,...

10.1186/s12864-019-5698-x article EN cc-by BMC Genomics 2019-05-14

<title>Abstract</title> <bold>Background</bold> The adverse effects of long-term exposure to particulate matter (PM<sub>2.5</sub>) have been found be closely associated with mortality. However, the relevant research on different levels in rural areas is insufficient China.<bold>Methods</bold> Based a multicenter population-based prospective study, adult residents (≥ 15 years old) from three study sites PM<sub>2.5</sub> were tracked for death events between 2013 and 2023. estimated values...

10.21203/rs.3.rs-6215443/v1 preprint EN Research Square (Research Square) 2025-04-17

Background To investigate the impact of major air pollutants on development tuberculosis (TB) among adults with latent infection (LTBI) in rural areas China. Methods Based a population-based multicenter cohort study conducted since 2013, we aimed to examine associations between various and risk active TB from LTBI. The estimates were assessed using time-dependent Cox regression models, non-linearity evaluated by restricted cubic splines. China High Air Pollutants datasets used feature...

10.1183/23120541.00390-2025 article EN cc-by-nc ERJ Open Research 2025-04-17

Background: Mainstream application of cancer immunotherapy is hampered by the low response rate most patients. A novel immunotherapeutic target or a biomarker predicting to needs be developed. Guanylate-binding protein 1 (GBP1) an interferon (IFN)-inducible guanosine triphosphatases (GTPases) involving inflammation and infection. However, immunological effects GBP1 in pan-cancer patients are still obscure. Methods: Using large-scale public data, we delineated landscape across 33 types. The...

10.3389/fgene.2022.820135 article EN cc-by Frontiers in Genetics 2022-02-10
Coming Soon ...